Sorafenib

Generic Name
Sorafenib
Brand Names
Nexavar, Sorafenib Accord
Drug Type
Small Molecule
Chemical Formula
C21H16ClF3N4O3
CAS Number
284461-73-0
Unique Ingredient Identifier
9ZOQ3TZI87
Background

Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...

Indication

Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.

In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.

Associated Conditions
Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
Associated Therapies
-
Clinical Trials
Related News

Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer

First Posted Date
2007-04-27
Last Posted Date
2015-12-16
Lead Sponsor
HealthPartners Institute
Target Recruit Count
16
Registration Number
NCT00466232
Locations
🇺🇸

Park Nicollet Institute, St. Louis Park, Minnesota, United States

Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)

First Posted Date
2007-04-24
Last Posted Date
2009-07-07
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
50
Registration Number
NCT00464919
Locations
🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma

First Posted Date
2007-04-18
Last Posted Date
2017-12-14
Lead Sponsor
Yale University
Target Recruit Count
17
Registration Number
NCT00461851
Locations
🇺🇸

Yale University, Comprehensive Cancer Center, New Haven, Connecticut, United States

Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma

Phase 2
Completed
Conditions
Lung Cancer
First Posted Date
2007-04-05
Last Posted Date
2010-03-04
Lead Sponsor
Swedish Medical Center
Target Recruit Count
5
Registration Number
NCT00456716
Locations
🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)

Phase 2
Terminated
Conditions
Metastatic Prostate Cancer
First Posted Date
2007-03-27
Last Posted Date
2011-09-16
Lead Sponsor
Accelerated Community Oncology Research Network
Target Recruit Count
22
Registration Number
NCT00452387
Locations
🇺🇸

Hematology Oncology Centers of the Northern Rockies, PC, Billings, Montana, United States

🇺🇸

The West Clinic, Memphis, Tennessee, United States

🇺🇸

Lancaster Cancer Center, Lancaster, Pennsylvania, United States

and more 7 locations

Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)

Phase 1
Completed
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: Sorafenib
First Posted Date
2007-03-27
Last Posted Date
2016-08-24
Lead Sponsor
University of Chicago
Target Recruit Count
12
Registration Number
NCT00452218
Locations
🇺🇸

The University of Chicago, Chicago, Illinois, United States

Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies

Phase 1
Completed
Conditions
Advanced Solid Tumor
Interventions
Drug: Sorafenib
Drug: Rapamycin
First Posted Date
2007-03-20
Last Posted Date
2013-06-12
Lead Sponsor
University of Chicago
Target Recruit Count
34
Registration Number
NCT00449280
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer

Phase 1
Completed
Conditions
Carcinoma, Renal Cell
Interventions
Drug: RAD001
Drug: Sorafenib
First Posted Date
2007-03-16
Last Posted Date
2016-03-17
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
55
Registration Number
NCT00448149
Locations
🇺🇸

The Methodist Hospital Research Institute, Houston, Texas, United States

Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

Phase 2
Completed
Conditions
Carcinoma, Renal Cell
Interventions
Drug: Sorafenib
First Posted Date
2007-03-08
Last Posted Date
2016-03-17
Lead Sponsor
The Methodist Hospital Research Institute
Target Recruit Count
71
Registration Number
NCT00445042
Locations
🇺🇸

Methodist Hospital - Baylor College of Medicine, Houston, Texas, United States

Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma

Phase 1
Completed
Conditions
Renal Cancer
Melanoma
Interventions
Drug: Aldesleukin
Drug: Sorafenib
First Posted Date
2007-01-04
Last Posted Date
2017-02-20
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
17
Registration Number
NCT00418496
Locations
🇺🇸

Ohio State University, Columbus, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy